WO2012122451A3 - Polymorphs of maxacalcitol and process for the preparation of maxacalcitol - Google Patents

Polymorphs of maxacalcitol and process for the preparation of maxacalcitol Download PDF

Info

Publication number
WO2012122451A3
WO2012122451A3 PCT/US2012/028426 US2012028426W WO2012122451A3 WO 2012122451 A3 WO2012122451 A3 WO 2012122451A3 US 2012028426 W US2012028426 W US 2012028426W WO 2012122451 A3 WO2012122451 A3 WO 2012122451A3
Authority
WO
WIPO (PCT)
Prior art keywords
maxacalcitol
polymorphs
preparation
pharmaceutical compositions
relates
Prior art date
Application number
PCT/US2012/028426
Other languages
French (fr)
Other versions
WO2012122451A2 (en
Inventor
Anchel Schwartz
Koby Wolfman
Michal RAFILOVICH -GIVON
Oleg Radchenko
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceutical Industries Ltd.
Priority to JP2013557893A priority Critical patent/JP2014514274A/en
Publication of WO2012122451A2 publication Critical patent/WO2012122451A2/en
Publication of WO2012122451A3 publication Critical patent/WO2012122451A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Abstract

The present invention relates to Maxacalcitol polymorphs and Maxacalcitol having low residual solvent content as well as processes for their preparation. The present invention also relates to pharmaceutical compositions containing Maxacalcitol polymorphs or Maxacalcitol having low residual solvent content and treatment methods using the pharmaceutical compositions.
PCT/US2012/028426 2011-03-09 2012-03-09 Polymorphs of maxacalcitol and process for the preparation of maxacalcitol WO2012122451A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013557893A JP2014514274A (en) 2011-03-09 2012-03-09 Polymorphs of maxacalcitol and methods for preparing maxacalcitol

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161450770P 2011-03-09 2011-03-09
US61/450,770 2011-03-09
US201161482477P 2011-05-04 2011-05-04
US61/482,477 2011-05-04
US201161487123P 2011-05-17 2011-05-17
US61/487,123 2011-05-17

Publications (2)

Publication Number Publication Date
WO2012122451A2 WO2012122451A2 (en) 2012-09-13
WO2012122451A3 true WO2012122451A3 (en) 2013-01-17

Family

ID=45894667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/028426 WO2012122451A2 (en) 2011-03-09 2012-03-09 Polymorphs of maxacalcitol and process for the preparation of maxacalcitol

Country Status (2)

Country Link
JP (1) JP2014514274A (en)
WO (1) WO2012122451A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5652723B2 (en) * 2012-08-17 2015-01-14 フォーモサ・ラボラトリーズ・インコーポレーテッド New crystal form of maxacalcitol
CN103508999B (en) * 2013-10-12 2015-05-13 浙江海正药业股份有限公司 Maxacalcitol synthesizing intermediate and preparation method and application thereof
CN107176918A (en) * 2016-03-09 2017-09-19 湖南华腾制药有限公司 A kind of purification process of Maxacalcitol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
JP3493037B2 (en) 1991-12-18 2004-02-03 中外製薬株式会社 22-oxacholecalciferol derivative and method for producing the same
EP1275643A4 (en) 2000-04-19 2009-06-03 Chugai Pharmaceutical Co Ltd Vitamin d derivatives
JP2002104995A (en) 2000-09-29 2002-04-10 Masahiko Hosaka Telomerase activity inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIMIZU, H. ET AL.: "Industrial Synthesis of Maxacalcitol, the Antihyperparathyroidism and Antipsoriatic Vitamin D3 analogue Exhibiting Low Calcemic Activity", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 9, 2005, pages 278 - 287, XP002675913 *

Also Published As

Publication number Publication date
JP2014514274A (en) 2014-06-19
WO2012122451A2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
MD20150091A2 (en) Anti-viral compounds
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014097151A3 (en) Autotaxin inhibitors
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
WO2013163190A8 (en) Dna-pk inhibitors
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2012168430A3 (en) Polypeptides
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
EA201892050A1 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2012029077A3 (en) Process for preparing fluticasone propionate/furoate
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2012122451A3 (en) Polymorphs of maxacalcitol and process for the preparation of maxacalcitol
WO2011112535A3 (en) Propionic acids, propionic acid esters, and related compounds
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
IN2014DN03010A (en)
WO2012177075A3 (en) Composition containing antibiotics and lysophosphatidylcholine for boosting immunity or treatment of bacterial infections
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2013557893

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12711067

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12711067

Country of ref document: EP

Kind code of ref document: A2